estradiol valerate / Generic mfg. - LARVOL DELTA

Efficacy of Daily 50 mg Intramuscular Progesterone for Luteal Phase Support in Frozen Embryo Transfer Cycles: Analysis of Serum Levels and Pregnancy Outcomes. (PubMed, J Family Reprod Health) - "Endometrial preparation began with oral estradiol valerate (6 mg/day) on cycle day 2...Serum P4 levels were measured on ET day, and oral dydrogesterone (20 mg/day) was added for patients with P4 levels 27.8 ng/mL) were associated with reduced chemical pregnancy rates, the absence of significant correlations with other pregnancy outcomes highlights the multifactorial nature of embryo implantation success. These findings emphasize the need for further research to refine P4 thresholds and identify additional predictive factors influencing pregnancy outcomes in FET cycles."

Journal

Oviductus Ranae alleviates D-galactose-induced ovarian aging by inhibiting ferroptosis and regulating the GPX4/ACSL4 pathway. (PubMed, J Ovarian Res) - "OR resists ovarian damage and prevents aging through antiferroptosis mechanisms by regulating the GPX4/ACSL4 axis in OGCs and aging rats. These results highlight the potential of OR as a therapeutic agent for the prevention and treatment of ovarian aging."

Journal • Metabolic Disorders • ACSL4 • GPX4 • LPCAT3 • SLC7A11

GnRH-a Pretreatment Doses and Frozen-Thawed Blastocyst Transfer Outcomes in PCOS Patients: A Retrospective Cohort Study. (PubMed, Int J Womens Health) - "Baseline characteristics were comparable among groups in age, duration of infertility, body mass index (BMI), endometrial thickness on the start day, estradiol (E2) and luteinizing hormone (LH) on the start day, endometrial thickness on the day of embryo transfer (ET), E2 on the ET day, and days of estradiol valerate administration (all P > 0.05)...The number of embryos transferred remains the primary determinant of pregnancy outcome. Larger prospective studies are warranted to validate these findings."

Journal • Retrospective data • Infertility • Polycystic Ovary Syndrome • Sexual Disorders

Development of polypropylene wound dressing coated with chitosan and Estradiol Valerate: A novel approach to chronic wound care. (PubMed, Int J Pharm) - "Also, the expression of collagen Type I gene was enhanced 3-fold increase in the PP/CS-500 in comparison with PP/CS-250 and control groups. Overall, coating the CS and Est on PP could be a promising formulation for the management of chronic wounds."

Journal • IL10 • IL6 • TGFB1 • TNFA

Clinical outcomes of different 17β-estradiol drug regimens and their impact on endometrial receptivity. (PubMed, Front Endocrinol (Lausanne)) - "Subjects were divided into three groups based on different estrogen formulations and administration routes: Group A [oral Estradiol Valerate Tablets (Progynova)], Group B (oral M17EH), and Group C (oral combined with vaginal M17EH)...For Groups B and C, endometrial tissue samples were collected five days after progesterone conversion...In FET cycles, a HRT regimen combining oral and vaginal administration of Micronized 17-beta estradiol hemihydrate is more conducive to endometrial growth. Although vaginal administration results in higher estrogen levels, it does not appear to compromise endometrial receptivity."

Clinical data • Journal • Retrospective data • Endometriosis • Hematological Malignancies • Leukemia • Oncology • LIF • MUC1

Impact of postoperative intrauterine therapies on IVF outcomes in patients with Asherman's Syndrome (ESGE 2025) - "Following catheter removal, a copper intrauterine device (IUD) was inserted, and patients received oral estradiol valerate (12–18 mg/day for 28 days) and oral medroxyprogesterone acetate (10 mg/day for the last 7 days). The complete resolution of menstrual disturbances and promising pregnancy results in both patient groups support the integration of tailored intrauterine therapies into routine clinical practice for endometrial rehabilitation prior to IVF. Further large-scale studies are warranted."

Clinical • Gynecology • Infertility • Long-acting Reversible Contraceptives • Mood Disorders • Pediatrics • Sexual Disorders • Women's Health

Endometrial regenerative therapy in patients with thin endometrium: A prospective case series (ESGE 2025) - "Postoperatively, all patients received standardized hormonal therapy with oral estradiol valerate (12–18 mg/day for 28 days) and oral medroxyprogesterone acetate (10 mg/day during the final 7 days) to induce withdrawal bleeding. The high clinical pregnancy and live birth rates observed in this cohort support the potential efficacy of this protocol. These findings underscore the need for further controlled trials to standardize treatment strategies and identify patients who may benefit most from regenerative intrauterine interventions."

Clinical • Gynecology • Infectious Disease

Chitosan/Alginate-Loaded Astragalus hamosus Shows Ameliorative Effects on Lipid Profile, Inflammatory and Hormonal Parameters, and Reduces miRNA-222 Expression in Polycystic Ovary Syndrome Rats. (PubMed, Reprod Med Biol) - "This study investigated the therapeutic effects of Chitosan/Alginate-loaded Astragalus hamosus extract (Chn/Al-AH) on the expression of miRNA-222 and ESR1 genes, inflammatory cytokines, lipid profile, and reproductive hormones in a rat model of polycystic ovary syndrome (PCOS) induced by estradiol valerate (EV)...Treatment with Chn/Al-AH significantly ameliorated these alterations by improving metabolic and endocrine profiles, reducing miRNA-222 expression, enhancing follicular development, decreasing cystic follicles, and promoting corpus luteum formation. Chn/Al-AH demonstrates therapeutic potential in mitigating hormonal, inflammatory, and genetic disruptions associated with PCOS in rats."

Journal • Preclinical • Dyslipidemia • Metabolic Disorders • Polycystic Ovary Syndrome • ER

Platelet-rich plasma therapy enhances endometrial receptivity in thin endometrium patients undergoing frozen embryo transfer cycles: results from a prospective cohort observational study. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "PRP therapy significantly enhances endometrial receptivity and improves pregnancy outcomes in patients with refractory thin endometrium. It offers a promising adjunctive treatment for patients facing repeated cycle cancellations in frozen embryo transfer."

Journal • Observational data

Linzia gerberiformis (Asteraceae) pretreatment prevents cognitive deficits induced by the combined effects of ovariectomy and chronic unpredictable mild stress in rats. (PubMed, Metab Brain Dis) - "Ovariectomized (OVX) female rats exposed to CUMS for 1 week were treated with distilled water, estradiol valerate (1 mg/kg), and the aqueous extract of L. gerberiformis leaves (75, 150, and 300 mg/kg) for 14 days starting from the 8th day after OVX...Pretreatment with L. gerberiformis aqueous extract leaves protects against the combined effects of ovariectomy and CUMS-induced memory deficits, suggesting its anti-amnesic properties. These properties could be mediated through the prevention of estrogen decline, modulation of the cholinergic system and oxidative stress."

Journal • Preclinical • Cognitive Disorders • Infectious Disease • Inflammation • Pain • Respiratory Diseases • CAT

COMPARATIVE STUDY OF PRP IN THIN ENDOMETRIUM IN PATIENTS UNDERGOING IUI (FIGO 2025) - "Patients in both the groups received standard estradiol valerate treatment... PRP stimulated ET and led to higher clinical pregnancy rate. Using it in intrauterine insemination cycles can reduce costs and psychological burden of this subgroup of women by reducing the need for resorting to advanced options such as in vitro fertilization and surrogacy."

Clinical • Gynecology • Infertility • Sexual Disorders

PULMONARY THROMBOEMBOLISM AFTER CONCURRENT SELF-MEDICATED HORMONE THERAPY IN A HIV TRANSGENDER WOMAN (FIGO 2025) - "At the beginning of 2023, the patient also started taking, every ten days, a non-prescribed monthly injectable contraceptive containing estradiol valerate 5 mg and norethisterone enanthate 50 mg. In April 2023, the patient took a dose of injectable medroxyprogesterone... Self-medication is a sociocultural phenomenon that persists even when medical care is available. Expanding provision of medical follow-up, providing safer options for those at increased risk for thromboembolic events, addressing expectatives and satisfaction of the patients with their hormone therapy, health education and mental health care are measures that can reduce the exposure of this population to such risks."

Clinical • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Long-acting Reversible Contraceptives • Pulmonary Disease • Pulmonary Embolism

Therapeutic efficacy of Rosa damascena Mill. on oxidative stress parameters and cyclooxygenase-2 gene expression in estradiol valerate-induced polycystic ovarian syndrome in Wistar rats. (PubMed, Sci Rep) - "The remaining rats-6 from the control group and 30 from the PCOS group-were assigned to five subgroups: a PCOS model group, a metformin-treated group (200 mg/kg/day), and three groups receiving RD extract at doses of 400, 800, or 1200 mg/kg/day for 28 days. Moreover, there was a significant decrease in Cox2 gene expression levels (P < 0.001). The RD extract showed potential therapeutic effects in alleviating PCOS complications, which seems partly due to improving the dysregulation of OS parameters."

Journal • Preclinical • Endocrine Disorders • Polycystic Ovary Syndrome • MT-CO2 • PTGS2

Mechanism of Tiaogeng decoction in a cognitive dysfunction mouse model. (PubMed, J Tradit Chin Med) - "TG may improve memory ability while reducing oxidative stress and apoptosis. It also reduces Aβ protein deposition in the hippocampus, protecting the central nervous system and improving memory function. TG may reduce the risk of AD."

IO biomarker • Journal • Preclinical • Alzheimer's Disease • B Cell Lymphoma • CNS Disorders • Cognitive Disorders • Lymphoma • Oncology • APP • BCL2 • CASP9 • HMOX1 • MAPK8 • NFE2L2

Comparison of clinical pregnancy rates between hormone replacement therapy and modified natural cycle for endometrial preparation in frozen embryo transfer cycles: An RCT. (PubMed, Int J Reprod Biomed) - "The HRC group received estradiol valerate until the endometrial thickness reached 8 mm, then daily injections of progesterone were added and FET were performed. Significant differences were observed in the number of monitoring visits between the mNC frozen embryo transfer and HRC groups (p = 0.001). Although the results indicate that the impact of both methods is similar, the fact that fewer visits are required in a natural cycle and there is also less need for hormones could make it preferable."

Clinical • Journal • Infertility • Sexual Disorders

Metabolic safety of gender-affirming hormonal treatment in transgender females. (PubMed, Sex Health) - "Methods The medical records of transgender women who received oral estradiol valerate and a gonadotropin-releasing hormone (GnRH) agonist for at least 18months were reviewed...However, the possibility of side effects is not well documented. The present study demonstrated that achieving estradiol and testosterone levels within therapeutic targets is important for the safety of gender-affirming therapy."

Journal • Dyslipidemia • Hematological Disorders • Hypertriglyceridemia • Severe Hypertriglyceridemia

Single-Center Retrospective Analysis of Safety and Efficacy of Subcutaneous Estradiol Use in Transgender and Nonbinary Adolescents and Young Adults. (PubMed, Transgend Health) - "A retrospective single-center chart review of TGNB adolescents and young adults up to 25 years old who received SC estradiol cypionate or SC estradiol valerate and completed laboratory testing between January 1, 2021, and January 1, 2024, was conducted. No clinically significant adverse events occurred, including new transaminase elevation, severe dyslipidemia, or thromboembolism. Many TGNB adolescents and young adults on SC estradiol administration achieved appropriate serum estradiol concentrations and no adverse events were reported, supporting continued use of SC estradiol in gender-affirming care."

Journal • Retrospective data • Cardiovascular • Dyslipidemia • Metabolic Disorders

The effects of metformin and sitagliptin for polycystic ovary syndrome treatment are enhanced by combining them. (PubMed, Eur J Pharmacol) - "This study was designed to evaluate and compare the effects of metformin, sitagliptin, and their combination in an estradiol valerate (EV)- induced animal model of PCOS. Furthermore, ovarian tissue structure was improved and the number of healthy follicles increased. These results suggest that the combination of metformin and sitagliptin, due to its multi-targeted effects, may be a more effective therapeutic approach than monotherapy for managing PCOS and warrants further clinical investigation."

Journal • Endocrine Disorders • Inflammation • Polycystic Ovary Syndrome • IL6

Impact of hormone replacement therapy on serum thyroid-stimulating hormone: a retrospective analysis. (PubMed, Reprod Biomed Online) - "HRT significantly increased TSH concentrations. Additionally, a TSH >2.5 mU/l did not correlate with miscarriage, but it was significantly associated with lower live birth rates. Further studies are needed to clarify HRT's impact on thyroid function and reproductive outcomes."

Journal • Retrospective data • Endocrine Disorders

Inducing agents and PCOS - A comprehensive analysis. (PubMed, J Steroid Biochem Mol Biol) - "Induction agents explored include androgens [Testosterone, Dihydrotestosterone (DHT), Dehydroepiandrosterone (DHEA)], estrogen (estradiol valerate), aromatase inhibitors (letrozole), endocrine disruptors (bisphenol A), and dietary modifications (high-fat or high-sugar diets). The selection of the agent and animal species based on research goals is vital for clinical relevance. Future work should focus on integrating models that reflect both reproductive and metabolic features of PCOS to improve translational value."

Journal • Review • Endocrine Disorders • Polycystic Ovary Syndrome

Live birth following multimodal therapy in a patient with asherman's syndrome, recurrent pregnancy loss, and polycystic ovarian syndrome: a case report and literature review. (PubMed, Contracept Reprod Med) - "This case highlights the complexities of managing TE induced by IUA using HA and assisted reproductive techniques. It also suggests that patients with TE complicated by PCOS and RSA can be treated with TAM, followed by estradiol valerate and HMG, to improve the EMT and pregnancy outcomes of FET."

Journal • Genetic Disorders • Gynecology • Polycystic Ovary Syndrome • Transplantation • Turners Syndrome

GRAPTOPHYLLUM PICTUM (ACANTHACAEA) RELIEVES THE HALLMARKS OF ENDOMETRIOSIS IN AN EXPERIMENTAL MODEL OF WISTAR RAT. (PubMed, Reprod Fertil) - "After verification of successful transplantation (42 days), the animals were co-treated for 7 days with estradiol valerate (E2V; 0.5 mg/kg and the aqueous (GPC) or methanolic (GPM) extracts of G. pictum at doses of 50 and 275 mg/kg. Positive controls received aspirin (3 mg/kg) or letrozole (10 mg/kg)...Apart from its ornamental worth, Graptophyllum pictum also called caricature plant, is traditionally used to relieve pain and treat reproductive disorders. After abdominal auto-transplantation of uterine fragments in rats, water-based and alcohol-based extracts of Graptophyllum pictum promoted fertility by improving menstrual pain, egg development; and reducing cell damage and inflammation, which contribute to the progression of endometriosis."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Endometriosis • Gynecology • Infertility • Musculoskeletal Pain • Oncology • Pain • Sexual Disorders • Transplantation • Women's Health • IL6 • TNFA

Lemongrass Alleviates Primary Dysmenorrhea Symptoms by Reducing Oxidative Stress and Inflammation and Relaxing the Uterine Muscles. (PubMed, Antioxidants (Basel)) - "PD was induced in female Wistar rats by administering estradiol valerate followed by oxytocin to induce PD symptoms. CcE efficacy was assessed at 30, 100, and 300 mg/kg concentrations and compared with ibuprofen...An in vivo analgesic assessment through hot-plate, tail-flick, and acetic acid-induced writhing assays showed good analgesic activity by CcE, while ex vivo experiments described tocolytic effects in rat uterine muscles. CcE alleviates PD by its antioxidant, anti-inflammatory, analgesic, and tocolytic effects."

Journal • Inflammation • Pain • Women's Health • IL10 • TNFA

Added administration of estradiol valerate tosurgical treatment for missed abortion in early pregnancy. (PubMed, Am J Transl Res) - "Oral administration of estradiol valerate followed by D&C demonstrates superior clinical efficacy in the management of missed abortion during early pregnancy. This can enhance cervical dilation, facilitate abortion, modulate estrogen levels, promote endometrial repair, and relieve inflammation."

Journal • Inflammation • Oncology • CRP • IL6 • TNFA

Intrauterine adhesion after missed miscarriage evacuation: efficacy of different estrogen doses on incidence and risk factors. (PubMed, Am J Transl Res) - "Preoperative administration of 5 mg/day estradiol valerate significantly reduces IUA incidence and enhances endometrial recovery after curettage. A thin endometrium and prior IUA history are key risk factors for postoperative adhesion formation."

Journal • Gynecology